Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c; Guides Lower
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.95 -0.83%
Revenue Growth %: +17.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +17.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $68 million versus the consensus estimate of $70.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2022 revenue of $240-280 million, versus the consensus of $313.62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
